Document:

Exhibit 10.1

 Exhibit 10.1 
 AMENDMENT NO. 2 TO RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENT 
 This
Amendment No. 2 to the Research and Exclusive License Option Agreement, dated as of November 27, 2012 (this “Amendment”), is made by and between Rexahn Pharmaceuticals, Inc., a corporation organized and existing under the laws of
Delaware (“Rexahn”), and Teva Pharmaceutical Industries Limited, a limited liability company organized and existing under the laws of Israel (“Teva”). Any capitalized term not defined herein shall have the meaning for such term
specified in the RELO Agreement (as defined below). 
 WHEREAS, Rexahn and Teva entered into a Research and Exclusive
License Option Agreement, dated June 26, 2009, as amended as of January 6, 2011 (the “RELO Agreement”); and 

WHEREAS, Rexahn and Teva desire to further amend the RELO Agreement as set forth herein; and 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, Rexahn and Teva agree as follows: 
 1. The RELO Agreement is amended by addition of
Section 2.1.13 stating: 
 “In the event Rexahn and Teva agree that further research and development for the R&D
Program is necessary, the Parties agree to incorporate as Annex 3 any then agreed upon update of the R&D Program, which update shall be deemed to be approved by the R&D Committee (the “Updated R&D Program”). The Parties also
agree that if the Updated R&D Program requires additional funding in amounts greater than the funds made or to be made available through Teva’s investments under the Securities Purchase Agreement, then Teva shall advance to Rexahn,
following receipt of invoice, such amounts as agreed to between the Parties, which shall be deemed to be approved by the R&D Committee, and the Parties agree to incorporate as Annex 4 the agreed upon Updated R&D Budget (the “Updated
R&D Budget”). If and to the extent that all of the updated R&D Budget is not expended under the updated R&D Program (due to over-budgeting, termination or otherwise), then Rexahn shall immediately return such remaining balance to
Teva. 
 2. The RELO Agreement is amended by addition of Annex 3 (Updated R&D Program) attached hereto as Exhibit A.

 3. The RELO Agreement is amended by addition of Annex 4 (Updated R&D Budget) attached hereto as Exhibit B.

 4. The RELO Agreement is amended by addition of Section 2.1.14 stating: 

“If Teva exercises its option to accept from Rexahn subcontract work relating to Material Task pursuant to Section 2.1.12, then
Teva shall have the right, at its sole option, to withhold from the amount of the Updated R&D Budget payable to Rexahn, the amount of funds equal to the subcontract fee payable to Teva” 

  
 1 

 5. Concurrently with the execution of this Agreement, Teva and Rexahn are entering into the
Second Amendment to the Services Agreement, pursuant to which the parties acknowledge and agree that Teva exercised its option under (a) Section 2.1.12 of the RELO Agreement to accept from Rexahn the subcontract work specified therein; and (b)
Paragraph 4 above to withhold from the amount of the updated R&D Budget payable to Rexahn the amount of funds equal to the subcontract fee payable to Teva under the Second Amendment to the Services Agreement. 

6. Section 5.2 of the RELO Agreement is hereby deleted in its entirety and replaced with the following: 

“Subject to Section 5.1, Teva shall have responsibility for undertaking clinical development of the Licensed Product and
preparing, submitting, seeking approval of, maintaining and updating marketing approval applications, marketing approvals and other regulatory approvals and applications for regulatory approvals in respect of the Licensed Product. Teva will solely
own, apply for and be the holder or owner of record for all applications and approvals relating to the Licensed Product, including without limitation, the filing of all INDs (which filings will be in Teva’s name). Without limiting the
generality of the immediately preceding sentence, Rexahn shall transfer and assign to Teva all regulatory filings, approvals and applications relating to the Licensed Product, and all related documentation and information. Subject to
Section 5.5, Teva will be solely responsible for commercializing the Licensed Product during the term of this Agreement, including, without limitation, manufacture, marketing, promotion, patient assistance programs, medical education, price
negotiation and setting, reimbursement negotiation, customer relations, sales, order processing, invoicing and collection, preparation of sales records and reports, warehousing, inventory management, logistics and distribution (including, without
limitation, the handling of returns, market withdrawals, field corrections and recalls).” 
 7. No Modification.
Except as specifically amended hereby, the RELO Agreement shall continue in full force and effect unmodified and the parties hereby reaffirm the same. 
 8. Governing Law. This Amendment shall be governed by, construed and enforced in accordance with the internal laws of the State of New York, without regard to principles of conflict of laws.

 9. Counterparts. This Amendment may be signed in any number of counterparts, each of which shall be an original and
all of which shall be deemed to be one and the same instrument, with the same effect as if the signatures thereto and hereto were upon the same instrument. A facsimile or electronic transmittal (e.g. pdf) signature shall be deemed to be an original
signature for purposes of this Amendment. 
 10. Amendment. The terms and conditions of this Amendment or RELO Agreement
may not be amended or waived, except with the prior written consent of each party hereto 

  
 2 

 IN WITNESS WHEREOF, the parties intending to be legally bound, executed this
Amendment No. 2 as of the date first above written. 
  

	
	REXAHN PHARMACEUTICALS, INC.
	
	 /s/ RICK SONI

	Rick Soni
	President & COO
	
	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
	
	 /s/ ITZHAK KRINSKY PHD.

	 Itzhak Krinsky Phd.
 Chairman
of Teva Japan,
 Chairman of Teva South Korea &
 Head of Business Development Asia Pacific

  

	
	 /s/ MIRELLA MOSHE

	 Mirella Moshe
 Head of Alliance
Management

	Corporate Business Development

  
 3EX-4.1

 Exhibit 4.1 
 FORM OF FIFTEENTH SUPPLEMENTAL INDENTURE 
 THIS FIFTEENTH SUPPLEMENTAL
INDENTURE is entered into as of                     ,         , by and between DDR Corp., an Ohio corporation
(the “Company”), and U.S. Bank National Association (the “Trustee”), a national banking association organized and existing under the laws of the United States, as successor trustee to U.S. Bank Trust National Association, as
successor to National City Bank. 
 WHEREAS, the Company and the Trustee entered into the Indenture dated as of May 1, 1994
(as supplemented by a First Supplemental Indenture dated as of May 10, 1995, by a Second Supplemental Indenture dated as of July 18, 2003, by a Third Supplemental Indenture dated as of January 23, 2004, by a Fourth Supplemental
Indenture dated as of April 22, 2004, by a Fifth Supplemental Indenture dated as of April 28, 2005, by a Sixth Supplemental Indenture dated as of October 7, 2005, by a Seventh Supplemental Indenture dated as of August 28, 2006,
by an Eighth Supplemental Indenture dated as of March 13, 2007, by a Ninth Supplemental Indenture dated as of September 30, 2009, by a Tenth Supplemental Indenture dated as of March 19, 2010, by an Eleventh Supplemental Indenture
dated as of August 12, 2010, by a Twelfth Supplemental Indenture dated as of November 5, 2010, by a Thirteenth Supplemental Indenture dated as of March 7, 2011 and by a Fourteenth Supplemental Indenture dated as of June 22, 2012
(the “Fourteenth Supplemental Indenture”), the “Indenture”), relating to the Company’s senior debt securities; 
 WHEREAS, the Company previously issued $300,000,000 initial aggregate principal amount of the Company’s 4.625% Notes due 2022 (the “Notes”), the specific terms and form of which were
established by the Fourteenth Supplemental Indenture; 
 WHEREAS, Section 301 of the Indenture provides that all Securities
of any one series need not be issued at the same time and, unless otherwise provided, a series may be reopened, without the consent of the Holders, for issuances of additional Securities of such series; 

WHEREAS, Section 4 of the Fourteenth Supplemental Indenture provides that the Company may, without the consent of the Holders,
create and issue additional Securities ranking pari passu with the Notes in all respects and so that such additional Notes shall be consolidated and form a single series having the same terms as to status, redemption or otherwise as the Notes
initially issued; 
 WHEREAS, the Company now desires to issue an additional $150,000,000 aggregate principal amount of the
Notes and has made a request to the Trustee that the Trustee join with it, in accordance with Section 901 of the Indenture, in the execution of this Fifteenth Supplemental Indenture to include such additional aggregate principal amount of the
Notes in the definition of Designated Securities such that the covenant in Section 1015 of the Indenture will inure to their benefit; and 
 WHEREAS, the Company and the Trustee are authorized to enter into this Fifteenth Supplemental Indenture. 

 NOW, THEREFORE, the Company and the Trustee agree as follows: 

Section 1. Relation to Indenture. This Fifteenth Supplemental Indenture supplements the Indenture and shall be a part and
subject to all the terms thereof. Except as supplemented hereby, the Indenture and the Securities issued thereunder shall continue in full force and effect. 
 Section 2. Capitalized Terms. Capitalized terms used herein and not otherwise defined herein are used as defined in the Indenture. 

Section 3. Definitions. 
 The definition of “Designated Securities” is hereby amended in its entirety as follows: 
 “Designated Securities” means the Company’s $300,000,000 principal amount of 4.625% Notes Due 2010, the Company’s $275,000,000 principal amount of 3.875% Notes Due 2009, the
Company’s $250,000,000 principal amount of 5.25% Notes Due 2011, the Company’s $200,000,000 principal amount of 5.0% Notes Due 2010, the Company’s $200,000,000 principal amount of 5.5% Notes Due 2015, the Company’s $350,000,000
principal amount of 5.375% Notes Due 2012, the Company’s $300,000,000 principal amount of 9.625% Notes Due 2016, the Company’s $300,000,000 principal amount of 7.50% Notes Due 2017, the Company’s $300,000,000 principal amount of
7.875% Notes Due 2020, the Company’s $300,000,000 principal amount of 4.75% Notes due 2018 and the Company’s $450,000,000 principal amount of 4.625% Notes due 2022. 
 Section 4. Aggregate Principal Amount. 
 The aggregate principal
amount of the Notes that may be authenticated and delivered under the Indenture, as amended hereby, shall be $450,000,000. The Company may, without the consent of the Holders, create and issue additional Securities ranking pari passu with the Notes
in all respects and so that such additional Notes shall be consolidated and form a single series having the same terms as to status, redemption or otherwise as the Notes previously issued. 

Section 5. Counterparts. This Fifteenth Supplemental Indenture may be executed in counterparts, each of which shall be
deemed an original, but all of which shall together constitute one and the same instrument. 
 Section 6. Governing
Law. THIS FIFTEENTH SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF OHIO (WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS PRINCIPLES THEREOF). 

  
 2 

 Section 7. Concerning the Trustee. The Trustee shall not be responsible for any
recital herein (other than the sixth recital as it appears as it applies to the Trustee) as such recitals shall be taken as statements of the Company, or the validity of the execution by the Company of this Fifteenth Supplemental Indenture. The
Trustee makes no representations as to the validity or sufficiency of this Fifteenth Supplemental Indenture. 
 [Signatures
follow.] 

 IN WITNESS WHEREOF, the parties hereto have caused this Fifteenth Supplemental Indenture to
be duly executed, and their respective corporate seals to be hereunto affixed and attested, all as of the day and year first above written. 
  

											
	Attest:	 		 	DDR CORP.
					
	  	 	  	 		 	By:	 	 
	 Name:
	 	 David E. Weiss
	 		 	    Name:	 	David J. Oakes
	Title:	 	 Executive Vice President,

General Counsel and Secretary
	 		 	    Title:	 	 Senior Executive Vice President and
 Chief Financial Officer

			
	Attest:	 		 	 U.S. BANK NATIONAL ASSOCIATION,
 as Trustee

					
	  	 	  	 		 	By:	 	 
	 Name:
	 		 		 	    Name:	 	
	Title:	 		 		 	    Title:	 	

 [Fifteenth Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]